About
CONSULTANT CARDIOLOGIST
Dr Gosia Wamil MD, MSc, PhD, FRCP, FESC,
Assistant Professor Mayo Clinic
Dr Wamil is a Consultant Cardiologist specialising in heart failure, cardiomyopathies and advanced cardiac imaging. She trained in cardiology at the Oxford University Hospitals. This included an internship in general medicine and fellowships in cardiovascular medicine, advanced cardiac imaging and heart failure. During that period, she earned formal accreditation in echocardiography, cardiac CT, and cardiac magnetic resonance. In addition to her clinical career, she is a clinician-scientist with research experience spanning molecular biology, drug development, and large-scale clinical trials. She completed the British Heart Foundation (BHF) MSc-PhD programme in Cardiovascular Science at the University of Edinburgh, followed by a postdoctoral BHF CRE fellowship in cardiac imaging at the University of Oxford. In her capacity as an expert in diabetes-related heart diseases, she is a member of the National Institute for Health and Care Excellence (NICE). She holds the role of an Honorary Senior Research Fellow at the Deep Medicine at the University of Oxford.
‘‘I am writing to offer my highest commendation for Dr. Gosia Wamil, whose professionalism set her apart as an exceptional physician for the Mayo Clinic, London. Dr. Wamil is a nice blend of medical brilliance and pure intelligence. As the parent of two doctors and one physician's assistant, I know brilliance when I see it. From the moment of my first contact, she instills confidence. Her follow up and ability to communicate reflect the very best. She listens empathically -- as I'm sure you know. Every interaction I've had with her reinforces the sense that one is in the hands of someone truly extraordinary—not just an excellent Doctor, but a wonderful person as well. As an aside, I've been seen by many at the Mayo Clinic, Scottsdale, over the last 40 years, and she, perhaps more than anyone else, exemplifies the distinct values that define the Mayo Clinic. It is not an overstatement to say that Dr. Wamil represents the best of the best. I feel elevated during and after our visits, which causes me to want to be healthier, not just for me, but to prove to her she is right path in her guidance. In short, I want to make her proud and be one more success story. Her work, no doubt, continues to enhance the Mayo Clinic’s legacy of world-class healthcare. Please extend to Dr. Wamil my deepest appreciation. Her care has left a memorable impression, and I consider myself fortunate to have been under her supervision.’’
O.L Mayo Clinic Healthcare in London March 2025
-
Heart failure
Heart diseases associated with Diabetes
Inherited Cardiomyopathies
Family screening
Hypertrophic cardiomyopathy
Dilated cardiomyopathy
Valve pathologies
Heart diseases of elderly people with co-morbidities
Cardiac computed tomography (CTCA)
Perfusion cardiac magnetic resonance (CMR) and stress echo (DSE)
Hypertension
High cardiovascular risk
-
MSc in Clinical Trials, University of Oxford 2024
PhD in Cardiovascular Science, University of Edinburgh 2008
MRCP RCP London 2009
MSc in Research, University of Edinburgh 2008
MD Medical University of Warsaw/Freie Universitaet in Berlin 2003
-
Fellow of the European Society of Cardiology
Royal College of Physicians
Society of Cardiovascular Magnetic Resonance
Society of Cardiovascular Computed Tomography
British Society of Echocardiography
British Society of Magnetic Resonance
European Society of Cardiovascular Imaging
-
Latest PubMed list of publications
Publications:
1. Rahimi K, Bidel Z, Nazarzadeh M, Coplan E, Canoy D, Wamil M, Majert J, McManus R; Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis, Lancet 26 Aug 2021 S0140-6736(21)01921-8.
2. Nazarzadeh M, Bidel Z, Coplan E, Canoy D, Wamil M, Majert J, Byrne K, Sundstrom J, Teo K, Davis B, Chalmers J, Pepine C, Dehghan A, Bennett D, Smith D, Rahimi K; Blood pressure lowering and risk of new-onset type 2 diabetes: evidence from genetic analysis and individual participant data meta-analysis of randomised controlled trials, Lancet 2021 Nov 13;398(10313):1803-1810
3. Wamil M, Coleman R, Adler IA, McMurray J, Holman RR; Increased Risk of Incident Heart Failure and All-cause Mortality in People with Insulin Resistance in the United Kingdom Prospective Diabetes Study: UKPDS; Diabetes Care 2021 Aug;44(8):1877-1884
4. Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Brady M, Hishmeh L, Attree E, Heightman M, Banerjee R, Banerjee A; COVERSCAN study investigators; Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study BMJ Open 2021 Mar 30;11(3): e 048391
5. Wamil M, McMurray JJ, Scott CAB, Coleman RL, Sun Y, Standl E, Rydén L, Holman RR Incidence, predictors, and importance of heart failure events in patients with impaired glucose tolerance in the Acarbose Cardiovascular Evaluation (ACE) trial, Diabetes Research and Clinical Practice 2020 Dec 170:108488
6. Wamil M, Borlotti A, Briosa e Gala A, Bracco A, Liu D, Piechnik S, Ferreira V, Alkalil M, DeMaria G, Fahrni G, Dawkins S, Wolfrum M, Banning A, Kharbanda R, Neubauer S, Choudhury R, Channon K, Dall’Armellina E Combined T1-mapping and tissue tracking analysis improves assessment of adverse LV remodeling following acute STEMI- an Oxford Acute Myocardial Infarction (OxAMI) study International Journal of Cardiovascular Imaging 2019 Jul, 5(7):1297-1308
7. De Ferrari G, Stevens S, Ambrosio G, Leonardi S, McGuire DK, Armstrong PD, Green JB, Wamil M, Holman RR, Peterson ED; on behalf of the TECOS Study Group; Low-Density Lipoprotein Cholesterol Treatment Patterns and Associated Outcomes in Patients with Type 2 Diabetes and Established Cardiovascular Disease: Insights from TECOS, American Heart Journal 2020 Feb;220:82-88
8. Wamil M, Bull S and Newton J. The modern role of transoesophageal echocardiography in the management of valvular pathologies. Echo Research and Practice Jan 17
9. Wamil M, Newton J and Bull S. TOE-what a general cardiologist needs to know? Heart 2017 Apr;103(8):629-640
10. Bajgent C, Laundray M et al. Collins R and SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 2011 Jun 9; 377(9784): 2181–2192
11. Digby, J, Martinez F, Jefferson A, Wamil M, Ruparelia N, Greaves D and Choudhury R. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Atherosclerosis, Thrombosis and Vascular Biology 2012 Mar;32(3):669-76.
12. Wamil M, Battle JH, Turban S, Kipari T, Peixoto RS, Fernbach D, Ramage L, Chapman KE, Hughes J, Dunbar D, Seckl JR and Morton NM. Depot-specific insulin-sensitizion and reduced inflammation drives the protective fat distribution of 11β-HSD1-/- mice. Diabetes 2011, Apr;60(4):1158-67.
13. Wamil M, Andrew R, Chapman K, Street J, Morton NM, Seckl JR. 7-oxysterols modulate glucocorticoid activity in adipocytes. Endocrinology. 2008, Dec;149(12):5909-18
14. Wamil M., Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discovery Today. 2007, Jul; 12(13-14):504-520.
15. Morton NM, Densmore V, Wamil M, Ramage L, Nichol K, Bünger L, Seckl JR and Kenyon CJ. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action Diabetes. 2005, Dec; 54(12):3371-8.
16. Snarski E, Kedzierska M, Wamil M, Prejbisz A, Pedzisz P, Wiktor-Jedrzejczak W. (2002, February 1). Time till diagnosis in blood neoplasia - an index of the efficiency of health care system? Acta Hematologica 33, 257-262.
17. Szopa M, Wamil M. (2007, May 20). 11beta-hydroxysteroid dehydrogenase type 1 inhibitor: a novel therapeutic target in the metabolic syndrome. Diabetologia Praktyczna 8, 77-83.
18. Maurin JK, Lasek W, Gorska A, Switaj T, Wamil M, Mlynarczuk I, Kazimierczuk Z. Synthesis, structure and tumour necrosis factor-alpha production-enhancing properties of novel adamantylamino heterocyclic derivatives. Anticancer Drug Design 2001, Apr; 16(2-3):73-80.
